Neomorph raises $100M to push its first molecular glue degrader into the clinic
What's the deal? San Diego-based Neomorph has closed a $100 million Series B to advance its pipeline of molecular glue degraders — a class of drugs that work by essentially instructing the body's own cellular machinery to destroy disease-causing proteins that conventional medicines cannot reach.
The round was led by Deerfield Management, Neomorph's founding investor, with new participants including Regeneron VenturesDealroom has a profile for this one. Try Dealroom → and Binney Street CapitalDealroom has a profile for this one. Try Dealroom →, the investment arm of the Dana-Farber Cancer InstituteDealroom has a profile for this one. Try Dealroom →. The company was founded in 2020.
Proceeds will primarily fund the ongoing Phase 1/2 clinical trial of NEO-811, Neomorph's lead asset, for a form of kidney cancer called clear cell renal cell carcinoma (ccRCC), as well as broader pipeline development.
Why now? Neomorph dosed its first patient in the NEO-811 trial in February 2026 — a key clinical milestone that de-risks the programme and justifies fresh capital. The trial is evaluating the drug as a monotherapy in patients with locally advanced or metastatic ccRCC, a disease with limited treatment options at late stage.
The raise also reflects strong validation from the pharma industry. Novo NordiskDealroom has a profile for this one. Try Dealroom →, BiogenDealroom has a profile for this one. Try Dealroom →, and AbbVieDealroom has a profile for this one. Try Dealroom → have all partnered with Neomorph across cardiometabolic disease, rare disease, neurology, oncology, and immunology — a breadth of partnerships that signals the platform's versatility beyond any single indication.
What could go wrong? Molecular glue degraders are a genuinely novel drug class, which means the clinical and regulatory path is less well-mapped than for conventional small molecules or biologics. NEO-811 is the first molecular glue degrader to enter a clinical trial targeting ARNT — a protein implicated in kidney cancer — and first-in-human trials carry inherent uncertainty around safety and tolerability. A setback at this stage would be costly both financially and reputationally.
The company is also still early: six years old, Series B, with a lead asset in Phase 1/2. The distance to a commercially approved drug is long and capital-intensive.
The signal: Neomorph's raise reflects accelerating investment in targeted protein degradation — a field that has moved from academic curiosity to serious drug discovery category in under a decade. The underlying logic is compelling: most disease-causing proteins are considered "undruggable" by conventional methods, meaning there is no small molecule that can block them effectively. Molecular glues and related technologies like PROTACs offer a way around that constraint by co-opting the cell's own disposal system.
The involvement of Dana-Farber's investment arm and Regeneron Ventures alongside Deerfield signals that both academic cancer medicine and commercial drug development are converging on this platform as a credible path to new medicines.
Sources:
Neomorph
GlobeNewswire
Business Insider
The Hamilton Spectator
Manila Times
J.V.
